Chemicals & Small Molecules

Drozitumab (PRO 95780) is a fully humanized antibody targeting the death receptor DR5 that shows anti-tumor activity against rhabdomyosarcoma, binds to the death receptor DR5 and induces apoptosis, and can be used in the study of triple-negative breast cancer.

Timolumab (BTT 1023), a fully human antibody targeting vascular adhesion protein-1 (VAP-1), attenuates fibrosis in a mouse model of liver injury and may be used to study primary sclerosing cholangitis.

Begelomab (SAND-26) is a murine monoclonal antibody targeting DPP-4/CD26. Begelomab can be used to study severe refractory inflammatory myopathies and drug-resistant acute graft-versus-host disease.

Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1) with potential antitumor activity for the study of the anti-PD-1 inhibitor budigalimab in non-small cell lung cancer.

Zenocutuzumab (MCLA-128) is a humanized bispecific IgG1 antibody with Fab arms targeting the extracellular domains of HER2 and HER3[1].

Zansecimab (LY-3127804) is a monoclonal antibody targeting angiopoietin 2 (Ang 2) for the study of cardiovascular and immune diseases.

Gancotamab (MM-302) is a HER2-targeting polyethylene glycolated liposome that encapsulates adriamycin to facilitate delivery to HER2-overexpressing tumor cells while limiting exposure to non-target tissues, including the heart.Gancotamab has antitumor activity and may be used to study advanced HER2-positive breast cancer.

Gontivimab (ALX-0171) is a trivalent nanobody targeting the hRSV fusion (F) protein with anti-RSV antiviral properties for the study of respiratory syncytial virus infections.

Imsidolimab (ANB 019) is a humanized anti-IL-36R monoclonal antibody that inhibits IL-36 signaling and can be used to study systemic pustular psoriasis.